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Summary Candida auris is an emerging antifungal resistant yeast species causing nosocomial
and invasive infections, emphasising the need of improved diagnostics and epidemio-
logical typing methods. We show that MALDI-TOF VITEK-MS followed by amplified
length polymorphisms allows for accurate species identification and subsequent
epidemiological characterisation of strains encountered during potential outbreaks.
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Introduction
Candida auris is an emerging pathogen first described
in 2009 as a species closely resembling C. haemulonii
and whose involvement in nosocomial fungaemia and
deep-seated infections have widely been reported sub-
sequently in East Asia.1–4 Notably, C. auris strains
appear to be clonal in Indian hospitals and exhibit
specific antifungal resistance.5,6 This underlines that
obtaining an accurate species identification and repro-
ducible antifungal susceptibility testing are crucial to
guide adequate therapy.7 However, C. auris is still fre-
quently misidentified as C. haemulonii based on current
taxonomy6–11 and use of presently available non-
MALDI-TOF commercial systems for yeast identifica-
tion. Conventional commercial yeast identification
methods seem to have come of age in the present era
of new diagnostic approaches.12 The aim of this study
was to determine if an accurate identification could be
obtained using the MS-VITEK matrix-assisted laser des-
orption ionisation time of flight mass spectrometry
(MALDI TOF MS or MALDI). Bruker MALDI has been
used successfully for the identification of a variety of
yeast species,13,14 including C. auris.9,10 The sec-
ondary aim of this study was to define if typing of the
strains would be feasible using MS-VITEK MALDI.
Material and methods
Knowledge base creation
Twelve reference strains of C. auris were used for the
VITEK MS knowledge base creation. Strains were inoc-
ulated on Sabouraud (SDA; bioMerieux, La Balme,
France) agar plates and incubated at 30 °C for 18 to
24 h prior to spectra acquisition.
Knowledge base testing and typing
The test of the expanded VITEK MS knowledge base
was then carried out on 50 additional independent
C. auris isolates that were not used to create the initial
database. All of the 50 tests C. auris isolates originated
from clinical specimens from three different countries
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(India n = 43, South Korea n = 2 and Brazil n = 5)
and were cultured on SDA plates incubated at 30 °C
for 48 h prior to spectra acquisition.
Amplified length polymorphisms (AFLP) typing
Amplified length polymorphisms was performed in par-
allel on 82 C. auris strains (India, n = 67; South
Africa, n = 6; Brazil, n = 5; Japan, n = 2; South Korea
n = 2) as described previously (6). Control isolates of
C. haemulonii (n = 4), C. duobushaemulonii (n = 4) and
C. pseudohaemulonii (n = 3), were included. AFLP data
were interpreted using the Pearson and UPGMA
algorithms.
MALDI
MALDI identification was performed using VITEK MS
Plus system (bioMerieux, Marcy l’Etoile, France) V2.0
according to the manufacturer’s instructions. Yeast
cells were deposited directly on the sample plate, cov-
ered by 0.5 ll of formic Acid (FA; bioMerieux) and
air-dried. One microlitre of a-cyano-4-hydroxy-cin-
namic acid matrix (CHCA; bioMerieux) was added to
each spot and air-dried before analysis.
Data exploration
Peak lists (2000–20 000 m/z) were imported into the
SARAMIS spectra base (bioMerieux) for further analy-
ses. Clusters were made to compare C. auris spectra to
those obtained for other common yeast species. Also,
multidimensional scaling analysis (MDS) was carried
out to evaluate the power of MALDI to discriminate
C. auris strains. This technique consists of representing
spectra as points in a usually two-dimensional space,
such that the distances between the points match the
observed dissimilarities as closely as possible. Dissimi-
larity matrix used in this study for MDS is based on
Spearman correlation.
Results and discussion
We successfully introduced C. auris as a new Candida
species in the VITEK MS clinical database. All isolates
of C. auris used to evaluate the performance of the
knowledge base were correctly identified to the species
level except four strains that were also found to be dis-
cordant by 18S. Cluster analysis of the MALDI spectra,
based on peak similarity, clearly discriminated C. auris
from other clinically relevant Candida species,
Figure 1 Cluster based on the relative
similarity of spectra from representative
isolates for the most common yeast spe-
cies present in the VITEK MS database
showing clear distinction between Can-
dida species. A similarity below 65% for
two spectra means that the strains
belong to different species.
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Figure 2 Dendrogram of amplified length polymorphisms analysis of Candida auris isolates from India, Japan, South Africa and South Korea
and members of an additional three different closely related Candida spp. It was constructed using UPGMA in combination with the Pearson
correlation coefficient and was restricted to fragments 60–400 base-pairs in length. The scale bar identifies the percentage similarity.
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including C. haemulonii (Fig. 1). Thus, VITEK MS
MALDI could be used to efficiently identify this emerg-
ing yeast species. Bruker MALDI has also been shown
recently to successfully identify this emerging
species.9,10
Further, VITEK MS MALDI in this study could differ-
entiate C. auris strains using the direct smear protocol.
MDS discriminated distinct groups of C. auris spectra
depending on the geographic origin of the strains
(data not shown). An overlap between Indian and
South African strains was observed, whereas strains
from Brazil, Korea and Japan made distinct subgroups.
These observations are in conformity with previous
studies using AFLP5,6,10 and the Bruker platform
demonstrating that the C. auris isolates from India are
clonal and distinct from Korean, Japanese and Brazil-
ian isolates. AFLP performed on the same set of strains
also identified geographic clusters of Indian and Brazil-
ian strains, whereas South African strains were ran-
domly distributed among Indian and Brazilian clusters.
Our data (Fig. 2) verified that AFLP reliably renders
information on geographic clustering and that C. auris
is efficiently segregated from C. haemulonii, C. pseudo-
haemuloni and C. duobushaemulonii isolates.10
Candida auris continues to be a worrisome non-albi-
cans species causing life threatening invasive diseases
such as pericarditis7 and fungaemia especially in
intensive care settings.5,6,8 We here show that VITEK
MS MALDI combined with AFLP allows rapid and
accurate identification and subsequent typing of this
emerging pathogen. Given the specific clinical charac-
teristics of C. auris, the application of one of these two
technologies will improve patient management.
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